The Chicago Sky have won two straight games, giving them a 2-4 record during the 2025 WNBA season. After losing their first three games by a combined 73 points, the Sky have responded by rising to ...

D Gukesh sealed a massive comeback win against Magnus Carlsen, taking advantage of a blunder in the end-game from a losing position. It looked like Magnus Carlsen would extend his lead in Norway ...

(RTTNews) - HUTCHMED (China) Limited (HCM) announced that results from the SACHI Phase III study represent a significant advancement in the treatment of EGFR mutation-positive NSCLC with MET ...

The former Iowa star dropped 11 points in just five minutes--a stretch that left even the WNBA in disbelief. "UNBELIEVABLE second quarter by @katemartin 勞" Thanks to Martin's heroics ...

HUTCHMED announced significant findings from the SACHI Phase III study, which investigated the combination of savolitinib and osimertinib in treating patients with locally advanced or metastatic ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in ...

WNBA Fans in Disbelief Over Angel Reese's Pass originally appeared on Athlon Sports. During her first year in the WNBA, Angel Reese dished out 1.9 assists per game. Playmaking isn't really her ...

On moving to Division III, I think the decision was made way before it happened. It’s a big decision, and I don’t want to hurt Saint Francis. It probably had to be done because of the finances.

its pivotal Phase III clinical trial. The current wet age-related macular degeneration (wAMD) treatment landscape is largely dominated by vascular endothelial growth factor (VEGF) inhibitors. Duravyu ...

NEW YORK – Intellia Therapeutics this week disclosed a serious adverse event in a patient participating in its Phase III MAGNITUDE trial, in which the biotech is testing its in vivo CRISPR ...

“PEACE III is the first major Phase III trial to combine an ARPI with radiopharmaceutical that showed statistical significance in meeting the primary endpoint,” said Denis Lacombe, Chief Executive ...

Data are reported for patients who completed week 16 of BE COMPLETE and entered the ongoing, phase III, open-label extension (OLE) study, BE VITAL. This manuscript reports data from the BE COMPLETE ...